Focused on the development of Innovative Drug Therapies
   
Pipeline
Contact Us
Acorn Biomedical, Inc. is a development stage biopharmaceutical company focused on the development of innovative drug therapies.
T-Fusion-TM Platform
latest news


Acorn Biomedical is developing first-in-class compounds targeting the Adenosine A3 receptor (A3AR), which modulate the production of aqueous humor in the eye. A3AR antagonists are a novel oral treatment for glaucoma.